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Summary
Geldanamycin, a polyketide natural product, is of sig-
nificant interest for development of new anticancer
drugs that target the protein chaperone Hsp90. While
the chemically reactive groups of geldanamycin have
been exploited to make a number of synthetic ana-
logs, including 17-allylamino-17-demethoxy geldana-
mycin (17-AAG), currently in clinical evaluation, the
“inert” groups of the molecule remain unexplored for
structure-activity relationships. We have used genetic
engineering of the geldanamycin polyketide synthase
(GdmPKS) gene cluster in Streptomyces hygroscopi-
cus to modify geldanamycin at such positions. Sub-
stitutions of acyltransferase domains were made in
six of the seven GdmPKS modules. Four of these led
to production of 2-desmethyl, 6-desmethoxy, 8-des-
methyl, and 14-desmethyl derivatives, including one
analog with a four-fold enhanced affinity for Hsp90.
The genetic tools developed for geldanamycin gene
manipulation will be useful for engineering additional
analogs that aid the development of this chemothera-
peutic agent.
Introduction
Geldanamycin [1–4] (Figure 1) and several other benzo-
quinone microbial products classified as ansamycin an-
tibiotics [5], herbimycin A [6, 7], macbecins [8], ansatri-
enins [9], and reblastatin [10, 11] were discovered between
1970 and 2000 in screens for antibacterial, antifungal,
and antiviral compounds. Interest in geldanamycin and
herbimycin A, however, increased greatly upon the dis-
covery of their antitumor properties [12, 13].
Geldanamycin was believed initially to interfere with
signal transduction pathways in tumor cells by direct
inhibition of oncogenic protein tyrosine kinases. How-
ever, Neckers and coworkers [14] showed in 1994 that
the principal cellular target is not a tyrosine kinase but
Hsp90, a ubiquitous and abundant protein chaperone
in mammalian cells [15]. Geldanamycin competes with
ATP for the ATP binding site of Hsp90, inhibiting its
ATP-dependent functions. One such function of Hsp90
is to chaperone nascent protein kinases that are critical
components of signal transduction pathways, many of
which are used by specific cancer cells [15]. In the
presence of geldanamycin, the immature kinases un-*Correspondence: mcdaniel@kosan.comdergo rapid degradation as a consequence of ubiquiti-
nation and subsequent catabolism by the proteosome.
The depletion of mature kinases results in a cytostatic
effect or, in some cases, apoptosis and cell death.
Thus, as a potential new target for cancer therapy, the
discovery that Hsp90 and one or more of its protein
kinase cohorts are overproduced in several types of hu-
man cancers has led to further interest in geldanamycin
and its analogs [16, 17].
Many geldanamycin analogs have been produced by
replacement of the C-17 O-methoxy group with substi-
tuted amines [18, 19]. One such drug, 17-allylamino-17-
demethoxygeldanamycin (17-AAG), is currently under-
going phase I and II clinical trials [20]. Experience with
the behavior of geldanamycin and 17-AAG in animals
and humans has pointed to the need for more water
soluble and less hepatotoxic forms of this drug [21, 22].
Hence, we decided to explore ways to use the geldana-
mycin biosynthesis genes [23] for production of new
geldanamycin analogs that could serve as the starting
point for the chemical synthesis of improved antican-
cer drugs.
Geldanamycin is made in Streptomyces hygroscopi-
cus by genes encoding a modular polyketide synthase
(PKS) and several tailoring enzymes. The pathway be-
gins with the formation of 3-amino-5-hydroxybenzoic
acid (AHBA) from glucose via kanosamine (cf. [24]). This
aromatic amino acid serves as the starter unit for poly-
ketide biosynthesis by the geldanamycin polyketide syn-
thase (GdmPKS), encoded by the gdmA1-A3 PKS genes
(Figure 2). Following elongation with the acyl-Coenzyme
A substrates malonyl-CoA, methylmalonyl-CoA, and
2-methoxymalonyl-ACP [25–27], the presumed polyke-
tide intermediate undergoes intramolecular lactamiza-
tion by GdmF to form progeldanamycin [23]. This is
then converted to geldanamycin by the action of at
least five tailoring enzymes (Figure 2) whose gene-
enzyme relationships have not been fully elucidated.
GdmN encodes the C-7 carbamoyltransferase [23] and
GdmM is likely to be involved in C-21 oxidation (unpub-
lished observation), but the remaining oxidation and
O-methylation steps have not been correlated with spe-
cific genes in the cluster.
Here, we report the production of several geldana-
mycin analogs by engineering of the GdmPKS. These
compounds were made by substituting the substrate
extender unit-encoding acyltransferase domains for
those with different specificities. This approach enables
alteration of carbon substituents around the macrolac-
tam, which could not be changed easily by chemical
modification. In the course of this work, an analog with
increased binding affinity for Hsp90 was identified.
Results
Design of AT Substitutions
The GdmPKS consists of seven polyketide chain exten-
sion modules preceded by an AHBA loading domain
(Figure 2). Each module contains an AT domain that
loads a malonyl (module 6), methylmalonyl (modules 1,
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(tender unit. Based on the precedent for substituting
amethylmalonate and/or methoxylmalonate with malo-
Anate extender units in the 6-deoxyerythronolide B syn-
bthase (DEBS) [28–32] and the FK520 PKS [33, 34], it
cwas reasoned that substitutions in which either methyl-
mmalonyl or methoxylmalonyl ATs (i.e., modules 1–5 and
O7) were replaced with a malonyl AT would have a high
lprobability of generating productive PKS mutants. The
arapAT2 domain, used extensively in AT domain swap
aexperiments, and/or the rapAT14 domain, both from the
erapamycin PKS [35], were therefore used to replace the
sAT domains in each of those modules. The boundaries
cbetween the AT and surrounding domains (Figure 3 and
sTable 1) used to create the hybrid modules were based
on either those used in DEBS experiments [31] (modules
21, 4, 5, and 7), FK520 PKS experiments [34] (modules 2
Kand 3), or a new set of junctions determined through
aoptimization experiments (to be reported elsewhere)
a(module 4). These replacements were expected to pro-
hduce 2-desmethyl, 6-desmethoxy, 8-desmethyl, 10-des-
Kmethyl, 12-desmethoxy, and 14-desmethyl geldana-
dmycin derivatives.
lThree different methods of gene manipulation were
Cdeveloped to make the AT replacements in the geldana-
pmycin-producing strain, Streptomyces hygroscopicus
dNRRL3602. For two methods, a set of donor cassettes
(was created containing the rapAT2 or rapAT14 cassette
Kflanked on either side byw1.0–1.3 kb of GdmPKS DNA.
bThese donor cassettes were then moved into either the
ctemperature-sensitive plasmid pKC1139 [36] or phage
KOS305-114, an apramycin-resistant derivative of the
2phage KC515 [37] (described in Experimental Pro-
cedures). The donor vectors were introduced by conju- (g
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Aation from E. coli (pKC1139) or by transfection
KOS305-114), and replacements occurred by stepwise
ouble crossing over as described in Experimental Pro-
edures. It was found that the pKC1139 plasmid as well
s the phage were highly unstable in this strain when
ntegrated in the chromosome, and, once a bona fide
ingle crossover was isolated, the second crossover
ccurred with high frequency (w50%) under nonselec-
ive conditions. AT swaps in modules 1, 2, 3, 5, and
were constructed in this manner (Table 2). The third
pproach employed a gene complementation host/vec-
or system in which Red/ET E. coli recombination [38,
9] was used to construct the AT swaps in an expres-
ion plasmid (pSET152) containing the gdmA2 and
dmA3 genes and integrated into a gdmA2A3 dele-
ion strain (see Experimental Procedures). AT replace-
ents in modules 4 and 5 were constructed in this
anner (Table 2).
roduction of Geldanamycin Analogs by AT Swaps
ermentation broth from each strain grown in pro-
uction media was analyzed initially by LC-MS. Strains
n which new compounds were detected were scaled
p, and the abundant compound(s) were purified and
haracterized by MS and NMR spectroscopies. Func-
ional AT substitutions were made successfully in four
f the six modules: modules 1, 4, 5, and 7 (Table 2). The
T substitutions in modules 1, 4, and 5 with rapAT2 all
ed to the expected analogs, 14-desmethyl-geldanamycin
KOSN1877), 8-desmethyl-geldanamycin (KOSN1859),
nd 6-desmethoxy-geldanamycin (KOSN1631) (Figure 4).
ll three of these compounds were modified completely
y the post-PKS tailoring reactions and were the major
ompounds present. A 4,5-dihydro derivative of 6-des-
ethoxy-geldanamycin (KOSN1630) was also isolated.
xidation of the C4-C5 positions is believed to be the
ast step of the pathway (see Discussion). The yield of
nalog in each case was lower (>10-fold) than the
mount of geldanamycin typically produced by the par-
nt wild-type strain. Swaps using rapAT14 were also
uccessful in modules 1 and 5 (Table 2) with no signifi-
ant differences in production levels compared to the
waps using rapAT2.
The substitution in module 7 produced three
-desmethyl compounds, KOSN1559, KOSN1558, and
OSN1619 (Table 2; Figure 4). The combined yield of
ll three compounds was substantially greater than the
nalogs described above and reached approximately
alf of the yield of geldanamycin normally observed.
OSN1559 and KOSN1558 were the two most abun-
ant products, present in roughly equal amounts. Both
ack the post-PKS oxidation reactions at C-17 and
-21 and the double bond at C4-C5. KOSN1558 ap-
ears to result from a polyketide pathway in which the
ehydration of C2-C3, catalyzed by the dehydratase
DH) domain of module 7, does not occur. Finally,
OSN1619 is an analog of KOSN1558 that lacks a car-
amoyl substituent. Reasons for the incomplete pro-
essing of these analogs are discussed below.
The AT substitutions that were attempted in modules
and 3 did not produce polyketide at detectable levels
Table 2).
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Progeldanamycin is the presumed polyketide product of the GdmPKS (encoded by gdmA1, A2, and A3) and GdmF (the lactam-forming amide
synthase). The GdmPKS consists of an AHBA loading domain and seven extension modules. Each module catalyzes one round of chain
elongation using malonyl-CoA (module 6), methylmalonyl-CoA (modules 1, 3, 5, and 7), or methoxymalonyl-ACP (modules 2 and 6). Each
module also modifies the β-carbonyl from each elongation to a hydroxyl (modules 3 and 5), alkene (modules 4 and 7), or methylene (modules
1, 2, and 6). Progeldanamycin is converted to geldanamycin by five steps, the precise order of which has not been determined. (KS-ketosyn-
thase, AT-acyltransferase, DH-dehydratase, ER-enolreductase, KR-ketoreductase, ACP-acyl carrier protein).Hsp90 Binding and Cytotoxic Activity
of Geldanamycin Analogs
Cytotoxicity of the analogs was assessed in SKBr3 cell
growth inhibition assays as previously described [19].
All of the compounds tested had substantially greater
IC50 values compared to geldanamycin and 17-AAG
(Table 3). The compounds also had similar or reduced
binding affinity for Hsp90 (Table 3). The exception was
KOSN1559, which binds to Hsp90 withwfour-fold greater
affinity than geldanamycin andweight-fold greater affin-
ity than 17-AAG.
Discussion
One of the major challenges faced with PKS engineer-
ing is the difficulty of performing genetic manipulations
in the actinomycete or other host organism harboring
the PKS gene cluster. This problem can sometimes be
overcome by heterologous expression of the gene clus-
ter in a more suitable organism, such as Streptomyces
coelicolor [40, 41]. However, very large gene clusters
or those for metabolites containing unusual precursorsFigure 3. Junctions Used for AT Domain Substitutions
Green sequences correspond to geldanamycin flanking regions,
blue to rapamycin ATs, and red to amino acids introduced by re-
striction site engineering.
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mthree different methods of gene manipulation were
developed for the geldanamycin-producing strain of o
rS. hygroscopicus. The gene complementation method
requires the greatest amount of development effort to m
mconstruct vectors and host strains. However, it also
provides the most flexibility and speed once estab- m
nlished. Therefore, for constructing a large number of
PKS gene manipulation experiments, this is the pre- p
gferred method. In addition to the compounds reported
here, the Red/ET cloning method has been used to pro- t
dduce geldanamycin analogs at the C6 ketone [42].
Substitution of AT domains has to date provided the c
egreatest number of polyketide analogs produced by
modular PKSs. Modification of polyketide structures t
sthrough AT engineering allows derivatives to be pro-
duced at positions that would otherwise be difficult or s
rimpossible to change by chemical modification. Here,
we have altered a methyl or methoxyl group at four c
Cpositions of geldanamycin previously unexplored for
structure-activity relationship, further demonstrating the i
robustness of this technique for making unique poly-
ketide analogs. Those AT swaps that failed to produce f
tthe desired analog likely resulted from a poor choice in
AT boundaries used to create the hybrid. Recent experi- s
pments have indicated that the location of AT boundaries
can make the difference between a functional and non- e
pfunctional hybrid [32, 43]. In fact, the AT4 substitution re-
ported here is a result of optimizing the location of the i
nboundaries from an initially failed swap (details of this
work will be reported elsewhere). Therefore, it is expected u
athat the replacements in modules 2 and 3 could be made
functional by repositioning the boundaries. dTable 1. Oligonucleotides Used in Plasmid Construction
AT1
Left flank for 5#-TTGAATTCAGATCTGGTTCGCTGCACGGCACCGACGTC
rev 5#-TTTCTAGAGGATCCGCCGTCTGTTCCGGTCTGTCCGGTG
Right flank for 5#-TTTCTAGACTGCAGCGCAACACCAGCGCAGGCGATGTG
rev 5#-TTAAGCTTATGCATCTCGGCGGTGTCGTGCACGGACAC
AT2
Left flank for 5#-TTGAATTCAGATCTGAGGACGCGGCCGGTTTCGACGCG
rev 5#-TTTCTAGACCTAGGGTGGCTCGTCTCCGGCCAGGGCCG
Right flank for 5#-TTTCTAGACTCGAGGCCACCGGCCACCACGGGGATGTC
rev 5#-TTAAGCTTATGCATCGCGGCGAACGCCCGGGTGTCGGC
AT3
Left flank for 5#-TTGAATTCAGATCTGCCGGAGACACGGCCGCCCCTGCC
rev 5#-TTTCTAGACCTAGGGTGTCCCGTCTCCGGCCAGGGCCG
Right flank for 5#-TTTCTAGACTCGAGCCGTCCGAGGTACCGGAGGCGGTG
rev 5#-TTAAGCTTATGCATCAGCCCGTCGAGGTAGGCGTTGCC
AT5
Left flank for 5#-TTGAATTCAGATCTGTGTTCGCCGGGGTCATCTACCAC
rev 5#-TTTCTAGAGGATCCGCCGTCGCTGCCCGTCTCCCCGGTG
Right flank for 5#-TTTCTAGACTGCAGCCCGCCAGGACACCGACGCGGGCC
rev 5#-TTAAGCTTATGCATGGCGTTGCCCGCCGCGTACGGGGC
AT7
Left flank for 5#-TTGAATTCAGATCTACGTCACTGCGCGGACAGGAGGTC
rev 5#-TTTCTAGAGGATCCGCCGTGGGTGGTGGCGTGGCCGGTG
for 5#-TTTCTAGACTGCAGCGCGGCGGTCCGGGCGACGTCCGT
rev 5#-TTAAGCTTATGCATCGGGTCGGTGACCTCGGCGGTGTC
EcoRI, BglII, XbaI, BamHI, PstI, HindIII, and NsiI restriction sites are underlinedIn many examples of PKS engineering, the changes
ade to the polyketide affect the activity or specificity
f post-PKS enzymes [43–46]. Three of the four changes
eported here were modified completely by the geldana-
ycin post-PKS enzymes. However, the substitution of
ethyl with hydrogen at C-2 of KOSN1559 has a dra-
atic impact on the oxidative modifications of the phe-
ol. Disruption of gdmM, encoding a monooxygenase,
roduced the 17-demethoxy-21-desoxy derivative of
eldanamycin, KOSN1806, which in turn affects forma-
ion of the C4-C5 double bond to produce the 4,5-dihy-
ro form (unpublished results). No evidence of quinone-
ontaining compounds was found in fermentation
xtracts of the AT7 substitution. Therefore, it appears
hat compounds lacking the C-2 methyl are very poor
ubstrates for GdmM. The structure of KOSN1559 also
upports the conclusion drawn from the gdmM dis-
uption that the post-PKS steps occur in the order of
arbamate attachment, oxidation of the phenol to the
-17 substituted quinone (the order of these two steps
s still ambiguous), and formation of the C4-C5 alkene.
Both KOSN1558 and KOSN1619 appear to result
rom bypassing of the DH domain in module 7 and
ransfer of the β-hydroxy intermediate to the down-
tream enzyme, GdmF. Again, disruption of activity ap-
arently results from the absence of a methyl substitu-
nt, in this case at the α-carbon of the ACP7-bound
olyketide intermediate. Bypassing of β-keto process-
ng activities has been observed previously in engi-
eered PKSs [31]. However, this is believed to be an
nprecedented example in which bypassing of an
ctive DH domain has been characterized. Unused DH
omains have been found often in sequenced PKSs;
Geldanamycin Polyketide Synthase Engineering
1629Table 2. Engineered Strains Containing Substitution of AT Domains in the Gdm PKS and Polyketides Produced
Method of
Strain AT Substitution Constructiona Analogs Produced Relative Yieldb
K309-9 AT1/rapAT2 1 KOSN1877 <0.05
K309-10 AT1/rapAT14 1 KOSN1877 <0.05
K390-31A AT2/rapAT2 2 —
K390-31B AT2/rapAT14 2 —
K309-3 AT3/rapAT14 1 —
K279-248/pKOS367-79 AT4/rapAT2 3 KOSN1859 <0.05
K309-2 AT5/rapAT2 1 KOSN1630 0.2
KOSN1631
K279-248/pKOS331-178 AT5/rapAT14 3 KOSN1630 0.2
KOSN1631
K309-1 AT7/rapAT2 1 KOSN1559 0.5
KOSN1558
KOSN1619
a1, KC1139 double crossover; 2, phage KOS305-114 double crossover; 3, gene complementation.
bApproximate combined yield relative to geldanamycin production under similar conditions.hepatotoxicity encountered with geldanamycin [49].3-R stereocenters for KOSN1558 and KOSN1619.
Figure 4. Geldanamycin Analogs Produced
by AT Substitutions in the GdmPKShowever, it is not obvious in many of those cases
whether the DH domain has been inactivated through
mutation or is simply bypassed. Based on the above
findings, it is possible that for many naturally occurring
DH domains that are apparently not used, the domain
remains active, but the rate of dehydration is slow rela-
tive to chain transfer to the next module. The relative
stereochemistry of the C3 hydroxyl of KOSN1558 and
KOSN1619 was not determined. However, based on
signature sequences in the KR domain of module 7 that
can correlated with product stereochemistry [47, 48], it
is predicted that reduction of the β-keto intermediate
would occur with D-configuration (B-type), leading toAll of the analogs engineered in this study possess
inferior cytotoxic activity toward SKBr3 cells compared
to geldanamycin and 17-AAG. However, KOSN1559
binds to Hsp90 with at least four-fold greater affinity. It
has become apparent in other studies [19], as well as
with KOSN1559, that relative Hsp90 binding is not a
predictive indicator of cytotoxicity. Preliminary experi-
ments suggest that the discrepancy between the tight
binding and low cytotoxicity of KOSN1559 may result
from poor intracellular accumulation of KOSN1559 in
SKBr3 cells (Z. Zhong, personal communication).
KOSN1559 is an attractive analog because it lacks the
quinone moiety believed to be a significant factor in
Chemistry & Biology
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aTherefore, it may be possible to create more potent and
csafer analogs of geldanamycin through chemical modi-
afications that improve cellular uptake while maintaining
[
enhanced Hsp90 binding affinity of KOSN1559. a
NSignificance [
t
17-AAG, an analog of geldanamycin, is a promising c
aanticancer agent that acts through a novel target,
oHsp90. In order to access new structures of geldana-
amycin that might improve the activity or pharmaco-
wlogical profile of 17-AAG, three different methods to ma- t
nipulate the polyketide biosynthetic synthase genes of C
geldanamycin were developed. These methods were o
3used successfully to exchange acyltransferase do-
vmains of the geldanamycin PKS, leading to production
tof geldanamycin analogs at positions that would be
s
very difficult to make by conventional chemical modi- m
fication. One of these methods, which uses a modi- f
fied cloning procedure based Red/ET recombination p
cin E. coli to introduce genetic modifications, along
with similar approaches developed recently by others
[50, 51], offers a potentially more efficient way to en- P
gineer PKS gene clusters. Finally, a 2-demethyl-4,5- C
Pdihydro-17-demethoxy-21-desoxy derivative of geldana-
gmycin was generated that binds to Hsp90 with eight-
pfold greater binding affinity than 17-AAG.
t
s
aExperimental Procedures
s
pBacterial Strains and Culture Conditions
S. hygroscopicus NRRL3602 was the strain used for chromosomal f
isubstitution of AT domains. Strain K279-248 (gdmA2,gdmA3::neo),
used for gene complementation experiments, will be described t
belsewhere. Plasmids were introduced into S. hygroscopicus by
conjugation using E. coli ET12657/pUZ8002 as donor on R5 agar
pplates containing 100 mg/l nalidixic acid. After incubating at 30°C
forw16 hr, exconjugants were selected with 3 ml soft nutrient agar t
jcontaining 1.5 mg apramycin. Liquid cultures were grown in R5
media [37] for 24–48 hr. Cells were grown on tomato agar plates a
t(per liter, 160 g tomato paste [Hunts], 80 g soy flour, 16 g calcium
carbonate, 8 g peptone, 160 g agar; post-sterilization: 80 g glu- X
mcose, 160 g sucrose, 8 g KH2PO4) for 7–10 days for sporulation.
S. hygroscopicus cultures and plates were incubated at 30°C or f
037°C to control the replication/propagation of temperature-sensi-
tive pKC1139 plasmids. S. hygroscopicus cultures grew more t
fslowly and eventually lysed after w36 hr at 37°C. Production of
geldanamycin and desired analogs was determined in geldana- i
wmycin-production medium (GPM) [2]. Seed cultures were grown in
liquid R5 medium for 2 days at 30°C, and 2 ml was used to inocu- c
flate 40 ml of GPM in 250 ml shake flasks at 30°C for 4 days.R
Table 3. Cytotoxicity and Hsp90 Binding Affinity of Geldanamycin 1
and Analogs D
PSKBr3 IC50 Hsp90 Kd
tCompound (nM) (nM)
d
Geldanamycin 41 670 X
17-AAG 33 1300 c
KOSN1631 (6-desmethoxy) 3200 5000 o
KOSN-1630 4900 3000 a
KOSN1859 (8-desmethyl) 480 5200 f
KOSN1877 (14-desmethyl) 470 660 E
KOSN1558 >5000 1000 B
KOSN1559 860 16 s
a
[eplacement of AT Domains in Modules
, 2, 3, 5, and 7 of GdmPKS
NA fragments, w1.0–1.3 kb each, flanking the AT domains were
CR amplified from cosmid pKOS256-107-3 with the oligonucleo-
ides in Table 1. The PCR fragments for each targeted AT were
igested and cloned together using EcoRI/XbaI (left flank) and
baI/HindIII (right flank) sites into pUC19. The rapAT2 or rapAT14
assettes were then inserted between the two flanking sequences
f each plasmid with BamHI and PstI restriction sites (AT1, AT5,
nd AT7) or AvrII and XhoI sites (AT2 and AT3). The ATs and flanking
ragments were moved into the delivery vectors pKC1139 [36] with
coRI and HindIII restriction sites or into phage KOS305-114 using
glII/NsiI. This phage was constructed by replacing the tsr cas-
ette between the BamHI and BglII sites of KC515 [37] with the
ac(3)IV apramycin-resistance gene excised from plasmid pHP45
37] with BamHI. The corresponding AT swap cassettes were
loned into circularized and digested phage DNA, and phage prop-
gation was performed as described by Kieser et al. [37]. The re-
ombinant phage constructs were confirmed by restriction analysis
nd introduced into S. hygroscopicus NRRL3602 by transfection
37]. Lysogens were selected on solid R5 using 2 ml of 1 mg/ml
pramycin overlay.
pKC1139 plasmids were introduced into S. hygroscopicus
RRL3602 by conjugation using E. coli ET12657/pUZ8002 as donor
37]. Primary exconjugants were first grown in 5 ml liquid R5 con-
aining 100 mg/l apramycin at 30°C for 2 days. To generate the first
rossover, 0.2 ml of these cells was used to inoculate 5 ml R5 with
pramycin and grown at 37°C for 36 hr. This step was repeated
nce, and cells were plated on R5 agar with apramycin or tomato
gar with apramycin at 37°C. Single colonies from these plates
ere grown, and their DNA was analyzed by Southern blot for in-
egration of the delivery plasmid by homologous recombination.
onfirmed single crossovers were propagated in R5 without antibi-
tic selection at 37°C for w32 hr, plated on tomato agar plates at
0°C, and allowed to sporulate (w10–14 days). Spores were har-
ested, plated on R5, and single colonies were screened for sensi-
ivity to apramycin. To identify the products of second crossovers,
ensitive colonies were screened for production of new geldana-
ycin compounds. Those strains producing new metabolites were
urther analyzed by PCR and/or Southern blot to verify the ex-
ected replacement of the targeted AT domain in the gdm gene
luster.
roduction of Geldanamycin and Analogs by Gene
omplementation in S. hygroscopicus NRRL3602
lasmid pKOS279-69 (to be described elsewhere) contains the
dmA2 and gdmA3 genes under control of the ermE* promoter in
SET152 [36]. Plasmids pKOS331-178 and pKOS367-79 are deriva-
ives of pKOS279-69 containing the AT5/rapAT14 and AT4/rapAT2
ubstitutions, respectively. Both plasmids were constructed using
modified two-step Red/ET cloning procedure [38, 39]. The first
tep introduces a selectable marker with unique restriction sites in
KOS279-69 that are used subsequently to linearize the plasmid
or the second recombination step. For the second step, the linear-
zed recipient plasmid and a linear donor AT cassette are used for
ransformation, thereby selecting for circularized plasmids formed
y recombination between the two linear fragments.
Plasmid pKOS331-178 was constructed as follows. Plasmid
KOS309-6a contains the left and right 1.3 kb fragments flanking
he AT5 domain, which are described in the preceding section,
oined together at their XbaI sites and inserted between the HindIII
nd EcoRI sites of pUC19. A 1.5 kb SpeI/XbaI fragment containing
he neomycin (neo) resistance marker of Tn5 was inserted into the
baI site of pKOS309-6a between the AT5 flanking fragments to
ake pKOS331-74A. A 3.1 kb linear DNA fragment was excised
rom pKOS331-74a with SacI and HincII. This fragment contains
.5 kb of the AT5 left flank, the 1.5 kb neo cassette, and 1.1 kb of
he AT5 right flank. Approximately 0.1 µg of the purified linear DNA
ragment was cointroduced with pKOS279-69 by electroporation
nto E. coli HS996/pSC101/BAD/γβαA (Gene Bridges), and colonies
ere selected with apramycin and neomycin. Colonies were
hecked by restriction enzyme analysis; approximately 60% were
ound to contain the neo marker recombined at the appropriate
Geldanamycin Polyketide Synthase Engineering
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and contains the gdmA2 and gdmA3 (AT5::neo) genes in pSET152.
The unique NsiI and AvrII restriction sites in the neo cassette were
used to linearize pKOS331-124 plasmid for the second cotransfor-
mation/recombination step. The delivery vector for this step,
pKOS305-124A, was constructed by inserting the rapAT14 cassette
into the BamHI and PstI restriction sites of pKOS309-6a. A 3.6 kb
linear DNA fragment containing the 1.3 kb AT5 left flank, the rapAT14
cassette, and the 1.3 kb AT5 right flank was excised from
pKOS305-124A with HindIII and EcoRI. Approximately 0.5 µg of the
purified linear DNA fragment was cointroduced with w0.3 µg of
linearized pKOS305-124A by electroporation into E. coli HS996/
pSC101/BAD/γβαA, and colonies were selected with apramycin.
One of eight colonies screened by restriction analysis was found to
contain the correct AT5/rapAT14 substitution and was designated
pKOS331-178. Plasmid pKOS367-79 containing the AT5/rapAT2
substitution was constructed by an analogous procedure, and de-
tails will be reported elsewhere.
Purification and Characterization of KOSN1559, KOSN1558,
KOSN1619, KOSN1630, and KOSN1631
Strains K309-1 and K309-2 were grown in flasks containing 38 ml
each GPM with 1.6 g XAD-16 (Rohm-Haas) beads inoculated with
2 ml seed culture each and grown at 30°C for 4 days. Contents of
flasks were pooled, centrifuged, and the supernatant was decanted
without losing any XAD. To separate cells from XAD beads, the
mixture was resuspended in water and the XAD beads were al-
lowed to settle. The supernatant with suspended cells was dec-
anted. This procedure was repeated two to three times until most
of the mycelium was gone. The XAD was then filtered using a sepa-
ration funnel with Whatman filter paper and washed briefly with
water. XAD was collected and extracted in 100% methanol (w1/10
of total fermentation volume) with stirring forw30 min. The metha-
nol was decanted, and the extraction was repeated twice. The
combined aqueous methanolic extracts were concentrated on a
rotary evaporator and freeze dried. The resultant brown residue
was resuspended in 120 ml of methanol and filtered. The filtrate
was evaporated to give a brown solid, which was redissolved in
dichloromethane/methanol. Silica gel was added to the solution,
and the mixture was evaporated to give a free-flowing powder. This
powder was loaded on a silica gel column and eluted with 0%–
20% methanol in dichloromethane. Major fractions were collected
and further purified by HPLC using a C-18 column (MetaChem Po-
laris 5µ C18-A 150 × 21.2 mm ID) and eluted using a gradient of
acetonitrile in water. Pooling of the column fractions was guided
by LC/MS. Three new compounds were obtained as white solids
after lyophilization of pooled fractions. Yields of purified com-
pounds were 35 mg/l KOSN1559, 15 mg/l KOSN1558, 10 mg/l
KOSN1619, 12 mg/l KOSN1630, and 10 mg/l KOSN1631.
2-Desmethylprogeldanamycin-7-Carbamate (KOSN-1559)
1H NMR (DMSO-d6, 400 MHz) δ (relative to DMSO-d5 at 2.49 ppm)
0.76 (d, 3, J = 6.4 Hz), 0.89 (d, 3, J = 6.4 Hz), 0.99 (m, 1), 1.29 (s, 3),
1.24–1.36 (m, 2), 1.49 (m, 1), 1.77 (m, 1), 2.14–2.24 (m, 4), 2.75 (br
d, 1, J = 10.0 Hz), 2.95 (br d, 1, J = 9.6 Hz), 3.19 (s, 3), 3.21 (m, 1),
3.27 (s, 3), 3.42 (m, 1), 4.47 (br s, 1), 4.82 (d, 1, J = 8.8 Hz), 5.19 (d,
1, J = 10.4 Hz), 5.90 (d, 1, J = 15.6 Hz), 6.13 (s, 1), 6.26 (s, 1), 6.37
(s, 1), 6.46 (br s, 2), 6.76 (dt, 1, J = 5.6, 15.6 Hz), 9.46 (s, 1), 9.48 (s,
1). 13C NMR (DMSO-d6, 100 MHz) δ (relative to DMSO-d6 at 39.5
ppm) 11.2, 17.7, 19.2, 26.1, 27.9, 31.6, 32.9, 34.7, 42.9, 56, 58.4,
72.4, 78.5, 81.2, 81.8, 108.3, 114.3, 118, 122.2, 129.4, 134.2, 138.6,
142.2, 143.7, 156, 157.7, 165.9. ESI TOF MS m/z 527.2712, calcu-
lated for C27H40N2O7Na ([M + Na]+), 527.2728.
3-Hydroxy-2,3-Dihydro-2-Desmethylprogeldanamycin-7-
Carbamate (KOSN-1558)
1H NMR (DMSO-d6, 400 MHz) δ (relative to DMSO-d5 at 2.49 ppm)
0.84 (br. m, 6), 1.19 (m, 1), 1.32 (m, 1), 1.38 (m, 1), 1.41 (s, 3), 1.49
(m, 2), 1.56 (m, 1), 1.65 (m, 1), 2.10 (m, 1), 2.28 (m, 1), 2.31 (m, 1),
2.43 (m, 1), 2.47 (m, 1), 3.07 (m, 1), 3.20 (br s, 6), 3.27 (m, 1), 3.38
(m, 1), 3.87 (m, 1), 3.98 (br s, 1), 4.81 (s, 1), 4.91 (s, 1), 5.22 (d, 1,
J = 8.0 Hz), 6.23 (s, 1), 6.37 (br s, 2), 6.66 (s, 1), 6.87 (s, 1), 9.20 (s,
1), 9.68 (s, 1). 13C NMR (DMSO-d6, 100 MHz) δ (relative to DMSO-
d6 at 39.5 ppm) 12.6, 16.3, 21, 25, 31.9, 32.7, 33.7, 34.4, 42.6, 45.5,
56.1, 57, 67.4, 73.3, 76.9, 79, 81.7, 104.8, 112, 112.7, 130.3, 130.5,139.2, 142.87, 156.4, 157, 168.9. ESI TOF MS m/z 545.2831, calcu-
lated for C27H42N2O8Na ([M + Na]+) 545.2833.
3-Hydroxy-2,3-Dihydro-2-Desmethylprogeldanamycin
(KOSN-1619)
1H NMR (DMSO-d6, 400 MHz) δ (relative to DMSO-d5 at 2.49 ppm)
0.85 (d, 3, J = 6.0 Hz), 0.87 (d, 3, J = 6.0 Hz), 1.23 (m, 1), 1.27–1.35
(m, 2), 1.29 (s, 3), 1.39 (m, 1), 1.57–1.63 (m, 2), 1.68 (m, 1), 2.19 (m,
1), 2.28 (m, 1), 2.31 (m, 1), 2.41–2.49 (m, 2), 3.09 (m, 1), 3.17 (m, 1),
3.20 (s, 3), 3.22 (s, 3), 3.32 (m, 1), 3.69 (br s, 1), 3.84 (m, 1), 3.99 (br
s, 1), 4.52 (d, 1, J = 6.0 Hz), 4.68 (br s, 1), 5.26 (d, 1, J = 8.8 Hz),
6.23 (s, 1), 6.71 (s, 1), 6.77 (s, 1), 9.25 (br s, 1), 9.61 (br s, 1). 13C
NMR (DMSO-d6, 100 MHz) δ (relative to DMSO-d6 at 39.5 ppm)
12.3, 16.5, 20.7, 24.8, 31.6, 32.1, 33.7, 34.1, 42.8, 45.7, 56.2, 57.1,
67.7, 73.6, 75.3, 80.9, 81.4, 104.6, 111.6, 112.0, 128.8, 133.8, 139.4,
142.4, 157.1, 169.0. ESI TOF MS m/z 502.2783, calculated for
C26H41NO7Na ([M + Na]+) 502.2775.
4,5-Dihydro-6-Desmethoxygeldanamycin (KOSN-1630)
1H NMR (CDCl3, 400 MHz) δ (relative to CHCl3 at 7.26 ppm) 0.90 (d,
3, J = 6.8 Hz), 0.95 (d, 3, J = 6.8 Hz), 1.63 (s, 3), 1.55–1.73 (m, 7),
1.85 (s, 3), 2.14 (m, 1), 2.37–2.43 (m, 2), 2.65–2.71 (m, 2), 3.32 (s, 3),
3.35 (m, 1), 3.54 (m, 1), 4.06 (s, 3), 4.92 (br s, 2), 5.12 (m, 1), 5.76 (d,
1, J = 5.6 Hz), 6.23 (t, 1, J = 6.4 Hz), 7.12 (s, 1), 8.66 (s, 1). 13C NMR
(CDCl3, 100 MHz) δ (relative to CDCl3 at 77.0 ppm) 11.0, 12.3, 13.0,
22.3, 24.6, 26.5, 28.4, 32.3, 32.4, 33.2, 35.0, 56.7, 61.5, 73.3, 80.5,
81.2, 111.0, 127.4, 132.4, 132.5, 132.8, 135.6, 138.1, 156.7, 156.9,
168.3, 184.1, 184.6. ESI TOF MS m/z 550.3102, calculated for
C28H44N3O8 ([M + NH4]+) 550.3123.
6-Desmethoxygeldanamycin (KOSN-1631)
1H NMR (CDCl3, 400 MHz) δ (relative to CHCl3 at 7.26 ppm) 0.87 (d,
3, J = 6.8 Hz), 0.95 (d, 3, J = 6.8 Hz), 1.59 (s, 3), 1.58–1.68 (m, 3),
1.96 (s, 3), 2.34–2.49 (m, 2), 2.52–2.57 (m, 2), 2.67 (m, 1), 3.32 (s, 3),
3.34 (m, 1), 3.64 (m, 1), 4.08 (s, 3), 4.87 (br s, 2), 5.10 (m, 1), 6.65 (d,
1, J = 5.6 Hz), 5.99 (m, 1), 6.41 (t, 1, J = 11.2 Hz), 6.97 (d, 1, J = 11.2
Hz), 7.20 (s, 1), 8.73 (s, 1). 13C NMR (CDCl3, 100 MHz) δ (relative to
CDCl3 at 77.0 ppm) 11.0, 12.3, 12.7, 22.5, 28.2, 31.9, 32.4, 33.4,
34.8, 56.6, 61.6, 73.0, 80.6, 81.2, 111.2, 124.9, 127.6, 128.7, 132.6,
133.1, 133.7, 136.9, 138.0, 156.5, 156.9, 168.5, 184.1, 184.8. ESI-
TOF-MS m/z 548.2928, calculated for C28H42N3O8 ([M + NH4]+)
548.2966.
Purification and Characterization of KOSN1859
Strain K279-69/pKOS331-178 was grown in 50 ml of YPD medium
(Sigma-Aldrich, St. Louis, MO) in a 250 ml flask for 1 day at 30°C,
and 25 ml was transferred into 500 ml YPD medium in a 2.8 l Fern-
bach flask. The culture was incubated at 30°C for 1 day, then used
to inoculate two 20 l bioreactors at 4% (v/v) each with 12 l of fer-
mentation medium (per liter, 2.5 g peptone [Difco], 2.5 g tryptone
[Difco], 2.5 g yeast extract [Difco], 5 g baby oatmeal [Gerber], and
10 g beet molasses [Minn-dak]). Glucose was added to a final con-
centration of 36.4 g/l with a sterile 650 g/l stock solution. Temper-
ature was maintained at 30°C. The pH was maintained at 6.5 with
2.5 N sulfuric acid or 2.5 N sodium hydroxide for 2 days after inocu-
lation and then at 6.0 thereafter. Dissolved oxygen was maintained
above 30% with agitation (200–400 rpm). Overhead pressure was
manually set at 6 PSI, and airflow was controlled at 1 vvm. Foam
was controlled by automatic addition of 50% (v/v) Antifoam B (JT
Baker).
Four days after inoculation, Celite (50 g/l) and Cycep 349 (2.5
ml/l) were added to the fermentation broth before filtering. The clar-
ified solution (23 l) was loaded on to a preconditioned HP20 column
(10 × 13 cm, 1 l). The column was eluted with 100% MeOH, and
the resulting mixture (4 l) was concentrated in vacuo to 250 ml. The
mixture was diluted to 25% MeOH and loaded on to a precondi-
tioned C-18 column (5 × 20 cm, 400 ml). The column was washed
with 50% MeOH (800 ml) and eluted with 60% MeOH. Fractions
containing the compound were pooled and dried to yield a dark
brown solid. The partially purified compound was further purified
by preparative HPLC on a Polaris C-18 column using 60% MeOH
as the mobile phase. KOSN1859 (470 mg) was isolated as a
brown solid.
8-Desmethylgeldanamycin (KOSN1859)
1H NMR (CDCl3, 400 MHz) δ (relative to CHCl3 at 7.26 ppm) 0.92 (d,
3, J = 6.0 Hz), 1.11 (s, 3), 1.53 (m, 1), 1.56 (m, 1), 1.83 (m, 1), 2.01
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1632(s, 3), 2.40 (m, 1), 2.44 (m, 1), 2.52 (m, 1), 3.35 (s, 3), 3.36 (s, 3), 3.60
(m, 1), 3.70 (t, 1, J = 6.0 Hz), 4.11 (s, 3), 4.26 (d, 1, J = 8.0 Hz), 4.90
(bs, 1), 5.38 (d, 1, J = 8.0 Hz), 5.84 (dd, 1, J = 8.0, 15.5 Hz), 5.86
(dd, 1, J = 8.0, 11.5 Hz), 6.22 (dd, 1, J = 7.0, 15.2 Hz), 6.54 (dd, 1,
J = 11.0, 11.4 Hz), 6.94 (d, 1, J = 11.5), 7.23 (s, 1), 8.8 (s, 1). 13C
NMR (CDCl3, 400 MHz) δ (relative to CHCl3 at 77.0 ppm) 12.3, 13.5,
21.8, 30.1, 30.9, 35.8, 36.9, 56.4, 57.8, 61.6, 74.0, 77.9, 79.9, 80.6,
111.4, 125.9, 126.3, 127.3, 127.6, 134.6, 136.8, 137.8, 139.1, 156.0,
157.1, 168.2, 184.1, 184.4. ESI TOF MS m/z 569.2470, calculated
for C28H38N2O9Na ([M +Na]+) 569.2466.
Purification and Characterization of KOSN1877
One 20 liter bioreactor was used to produce KOSN1877. The fer-
mentation of strain K309-9 was conducted as above for
KOSN1859, except the pH was controlled at 6.0 throughout the
process, and the airflow was set at 0.75 vvm. The filtered broth was
loaded on to a preconditioned HP20 column, washed with 40%
1
methanol (2 l), and eluted with 100% methanol (5 l). Fractions con-
taining the compound were pooled and concentrated to 425 ml.
The crude mixture was diluted with 850 ml water and loaded on to
1
a C-18 column (3 × 15.5 cm, 110 ml). The column was washed with
40% MeOH (100 ml), eluted with 1 l 50% methanol, and rechro-
matographed over C-18 using the same conditions. Fractions con-
taining compound were pooled and dried to a dark brown solid.
The solid was dissolved in dichloromethane and extracted once 1
with water. The organic extract was dried to a give a yellow solid,
dissolved in dichloromethane:MeOH (2:1), and further purified by
preparative HPLC using 55% MeOH:water as the mobile phase.
KOSN1877 (164 mg) was isolated as a yellow-colored solid. 1
14-Desmethylgeldanamycin (KOSN1877)
1H NMR (CDCl3, 400 MHz) δ (relative to CHCl3 at 7.26 ppm) 0.88 (d,
3, J = 7.0 Hz), 1.41 (m, 1), 1.52 (m, 1), 1.57 (m, 1), 1.79 (s, 3), 1.98
(m, 1), 2.0 (s, 3), 2.42 (m, 1), 2.64 (m, 1), 2.78 (m, 1), 3.29 (s, 3), 3.29 1
(m, 1), 3.31 (s, 3), 3.56 (d, 1, J = 7.0 Hz), 4.10 (s, 3), 4.31 (d, 1, J =
9.0 Hz), 4.95 (bs, 2), 5.16 (s, 1), 5.73 (d, 1, J = 9.0 Hz), 5.86 (dd, 1,
J = 9.5, 10.0 Hz), 6.55 (dd, 1, J = 11.0, 11.0 Hz), 6.96 (d, 1, J = 9.5),
7.22 (s, 1), 8.73 (s, 1). 13C NMR (CDCl3, 400 MHz) δ (relative to CHCl3
at 77.0 ppm) 12.4, 12.6, 12.9, 20.4, 23.7, 25.9, 32.3, 56.6, 57.3, 61.7,
72.3, 80.4, 81.0, 81.3, 111.4, 126.3, 127.6, 128.2, 132.5, 133.5, 134.7, 1
136.3, 138.1, 156.1, 156.4, 168.2, 184.1, 184.5. ESI-TOF-MS m/z
569.2469, calculated for C28 H38N2O9Na ([M+Na]+) 569.2466. 1
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